Emerging Targeted Therapies for HER2-Positive Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is a leading cause of death in women, with HER2 overexpression impacting prognosis.
• Trastuzumab is a standard HER2-targeted therapy, but resistance affects approximately one-third of patients.
• The emergence of HER2-low breast cancer necessitates novel therapeutic approaches.

Purpose of the Study:

• To review current HER2-targeted therapies for breast cancer.
• To discuss the challenges and limitations of existing treatments, including resistance.
• To explore potential novel combinations and future directions for HER2-targeted strategies.

Main Methods:

• Literature review of HER2-targeted therapies.
• Analysis of clinical data on treatment efficacy and resistance.
• Exploration of emerging therapeutic combinations and modalities.

Main Results:

• Several HER2-targeted agents exist, including monoclonal antibodies, antibody-drug conjugates (e.g., T-DM1, T-DXd), and tyrosine kinase inhibitors.
• Trastuzumab-deruxtecan (T-DXd) shows efficacy in HER2-low breast cancer, indicating broader potential for HER2-targeted treatments.
• Despite available therapies, treatment options are limited for patients with progressive or resistant disease.

Conclusions:

• HER2-targeted therapies have evolved, but resistance remains a significant clinical challenge.
• Further research into novel combinations, including immunotherapy and cell-based therapies, is crucial.
• Developing strategies for HER2-low and resistant breast cancer subtypes is essential for improving patient survival.